Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease

Ng, Ying Zhuang; Lai, Lee Lee; Wong, Sui Weng; Mohamad, Siti Yatimah; Chuah, Kee Huat; Chan, Wah Kheong

doi:10.1371/journal.pone.0250300

Cited by 10 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ng and coworkers demonstrated a strong correlation (r = 0.76, p < 0.001) between the attenuation values obtained using the FibroScan and FibroTouch on the cohort of 163 patients with CLD of various etiologies. They also found the good to excellent intra- and inter-observer agreement [ 57 ].…”

Section: Quantitative Ultrasound-based Methodsmentioning

confidence: 99%

Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal

et al. 2022

View full text Add to dashboard Cite

The prevalence of the non-alcoholic fatty liver disease has reached major proportions, being estimated to affect one-quarter of the global population. The reference techniques, which include liver biopsy and the magnetic resonance imaging proton density fat fraction, have objective practical and financial limitations to their routine use in the detection and quantification of liver steatosis. Therefore, there has been a rising necessity for the development of new inexpensive, widely applicable and reliable non-invasive diagnostic tools. The controlled attenuation parameter has been considered the point-of-care technique for the assessment of liver steatosis for a long period of time. Recently, many ultrasound (US) system manufacturers have developed proprietary software solutions for the quantification of liver steatosis. Some of these methods have already been extensively tested with very good performance results reported, while others are still under evaluation. This manuscript reviews the currently available US-based methods for diagnosing and grading liver steatosis, including their classification and performance results, with an appraisal of the importance of this armamentarium in daily clinical practice.

show abstract

Section: Quantitative Ultrasound-based Methodsmentioning

confidence: 99%

Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the assessment of hepatic steatosis, scattering occurs when the incident ultrasonic wave encounters lipid droplets contained in hepatic cells. This results in increased ultrasonic attenuation, which correlates with the severity of fatty liver disease ( 17 , 18 ). According to the standards outlined in the Expert Consensus on Clinical Application of Transient Elastography (TE) and based on the liver fat attenuation results detected by FibroTouch, patients with MAFLD were diagnosed as having mild fatty liver (CAP 240–265 dB/m), moderate fatty liver (CAP 265–295 dB /m), or severe fatty liver (CAP > 295 dB/m) ( 19 ).…”

Section: Methodsmentioning

confidence: 99%

Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial

et al. 2022

View full text Add to dashboard Cite

Background:Metabolic dysfunction-associated fatty liver disease (MAFLD) affects people at an increasingly younger age. The primary treatment for patients with MAFLD is diet-induced weight loss; however, excessive dieting is poorly effective.ObjectivesThe aim of this trial was to evaluate whether a high protein and low glycemic index (HPLG) dietary intervention would result in improvement of controlled attenuation parameter (CAP) and related metabolic markers in MAFLD.MethodsA 12-week controlled, parallel-group, randomized intervention trial was performed. A number of 63 participants with MAFLD were enrolled and randomized between the HPLG dietary group and the balanced diet control group. Both diets had the same hypocaloric level and were prescribed ad libitum within food limit lists. The primary outcome was CAP. The main secondary outcomes were weight loss and improvement of metabolism-related indexes at week 12 after the program initiation.ResultsA total of 59 participants completed the intervention and were included in the final analysis. The mean age was 39.3 ± 8.9 years and 66.1% were men. In this trial, protein and carbohydrate intakes were significantly higher and lower, respectively, in the HPLG group compared to controls (p < 0.001). At week 12, CAP was significantly reduced in both groups (p < 0.001). However, a significantly greater reduction in liver fat was observed in the HPLG group compared to the control group (p = 0.011), with mean relative reductions of 30.90 dB/m (95% CI, 21.53 to 40.26, p < 0.001) and 15.43 dB/m (95% CI, 7.57 to 23.30, p < 0.001), respectively. From baseline to week 12, a significantly greater loss in bodyweight was recorded in participants in the HPLG group (6.52 kg; 95% CI, 5.50 to 7.54, p < 0.001) compared to control subjects (2.00 kg; 95% CI, 0.89 to 3.11, p = 0.001). Moreover, body fat percentage in the HPLG group was significantly reduced compared with the control group (p = 0.002). Within-group improvements in visceral fat, blood pressure, cardiovascular risk factors, and blood glucose-related indicators were detected in patients with MAFLD assigned to the HPLG diet (p < 0.05), but not in those prescribed the control diet (p > 0.05).ConclusionUnder our experimental conditions, and compared to the traditional balanced diet, an HPLG diet led to a significant CAP remission, bodyweight or fat reduction, and improvement of metabolic markers in patients with MAFLD.Clinical Trial RegistrationClinicalTrials.gov, identifier: NCT03972631.

show abstract

“… 27 In a study on patients with chronic liver disease of various etiologies, the UAP has been shown to correlate strongly with CAP. 28 The main advantage of attenuation parameter for diagnosis of hepatic steatosis is that the result is available simultaneously with liver stiffness measurement and can help diagnose hepatic steatosis in patients with other causes of chronic liver disease undergoing liver stiffness measurement. It is important to identify and manage hepatic steatosis and metabolic risk factors to improve overall outcome of patients with other causes of chronic liver disease.…”

Section: Non-invasive Assessment Of Hepatic Steatosismentioning

confidence: 99%

“…Similar to attenuation parameter, liver stiffness measurement obtained using the FibroTouch strongly correlated with the Fibroscan; however, liver stiffness measurement (and attenuation parameter) obtained using FibroTouch tended to be higher at lower values and lower at higher values. 28 MRE more accurately classifies fibrosis than liver stiffness measurement by transient elastography; 31 however, as mentioned earlier, its use in routine clinical practice is limited by cost and availability.…”

Section: Non-invasive Assessment Of Hepatic Fibrosismentioning

confidence: 99%

See 1 more Smart Citation

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease

Kumar

Skantha

Chan

2022

Therapeutic Advances in Endocrinology

Self Cite

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) affects an estimated one-quarter of the global adult population and has become one of the leading causes of end-stage liver disease and hepatocellular carcinoma with increased liver-related and overall morbidity and mortality. The new term, metabolic dysfunction–associated fatty liver disease (MAFLD), has a set of positive diagnostic criteria and has been shown to have better clinical utility, but it has yet to be universally adopted. This review addresses the non-invasive tests for MAFLD and is based mostly on studies on NAFLD patients, as the MAFLD term is relatively new and there are limited studies on non-invasive tests based on this new term, while a large body of research work on non-invasive tests has accumulated in the literature for NAFLD. This review focuses on blood-based biomarkers and scores for the assessment of hepatic steatosis, non-alcoholic steatohepatitis (NASH), and fibrosis, and two of the most widely studied imaging biomarkers, namely vibration-controlled transient elastography and magnetic resonance imaging. Fibrotic NASH has become a diagnostic target of interest and novel serum biomarkers and scores incorporating imaging biomarker for diagnosis of fibrotic NASH are emerging. Nonetheless, the degree of liver fibrosis remains the key predictor of liver-related morbidity and mortality in patients with MAFLD. A multitude of non-invasive biomarkers and scores have been studied for the detection of liver fibrosis, including use of sequential non-invasive tests for risk stratification of advanced liver fibrosis. In addition, this review will explore the utility of the non-invasive tests for prognostication and for monitoring of treatment response.

show abstract

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease

Cited by 10 publications

References 22 publications

Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal

Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal

Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease

Contact Info

Product

Resources

About